Ken Yamada

Interactive, case study-led workshop exploring how leading developers are overcoming the biological barriers limiting oligonucleotide delivery beyond the liver. Through realworld development examples and collaborative discussion, attendees will evaluate the trade-offs between emerging targeting platforms and leave with a practical framework for selecting the right delivery strategy for their own programmes.

Workshop highlights

• Work through real-world case studies of extrahepatic and CNS delivery programmes to understand where promising approaches translated successfully and where they broke down between preclinical models and the clinic
• Compare transferrin receptor conjugates, antibody shuttles, ligand-based targeting and non-conjugated approaches to determine which strategy is best suited to different tissues, indications and therapeutic modalities
• Leave with a practical framework to identify whether delivery strategy, targeting ligand or oligonucleotide chemistry represents the greatest development risk in your programme and where to focus optimisation efforts first